Deep Dive Comparison • Updated November 28, 2025
Mounjaro vs Wegovy: Complete Comparison Guide
If you are considering injectable GLP-1 medications for weight management, the choice often comes down to Mounjaro (Tirzepatide) vs Wegovy (Semaglutide). This comprehensive, educational guide breaks down the science, trial data, side effects, and costs so you can have an informed conversation with a licensed healthcare provider.
Quick Answer
In short: Mounjaro (Tirzepatide) shows up to 22.5% average weight loss in clinical trials compared with Wegovy’s 15% average weight loss. However, Wegovy (Semaglutide) often has more affordable compounded options starting around $99/month and a longer track record. Both require a valid prescription, medical evaluation, and lifestyle changes to be effective.
Important Educational Disclaimer
This article is for educational purposes only. MounjarovsWegovy.com is an independent comparison website. We do not prescribe medications, we are not a telehealth provider, and we are not affiliated with Eli Lilly or Novo Nordisk. Always consult a licensed healthcare provider before starting or switching GLP-1 medications.
Table of Contents
At-a-Glance Comparison
| Metric | Mounjaro (Tirzepatide) | Wegovy (Semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
| Average Weight Loss | Up to 22.5% (SURMOUNT-1) | Up to 15% (STEP-1) |
| Starting Dose | 2.5 mg weekly | 0.25 mg weekly |
| Maintenance Dose | Up to 15 mg weekly | 2.4 mg weekly |
| Brand Retail Price | $1,023-$1,349/month | $1,349/month |
| Compounded Pricing | Typically $199-$649/month via telehealth | Typically $99-$549/month via telehealth |
How They Work
Tirzepatide
Mounjaro & Zepbound
Tirzepatide is the first-in-class dual agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. The combined signaling improves insulin secretion, slows gastric emptying, suppresses appetite, and may impact fat metabolism more strongly than GLP-1 alone. This dual action is likely responsible for the higher average weight-loss percentages reported in the SURMOUNT trials.
Semaglutide
Wegovy & Ozempic
Semaglutide is a potent GLP-1 receptor agonist. It mimics the hormone GLP-1, which is released after meals to signal satiety, reduce gastric emptying, and support insulin secretion. By extending the GLP-1 signal, Wegovy helps patients eat smaller meals, feel fuller longer, and improve blood sugar control. The STEP trials established Semaglutide as the first once-weekly injectable to gain FDA approval specifically for chronic weight management.
Think of Tirzepatide vs Semaglutide as a dual-engine vs single-engine approach. The dual engine provides more power but can be more expensive and harder to source, while the single engine is proven, widely available, and often more affordable.
Clinical Trial Results
Clinical trial data provide the most objective comparison. Both drug makers conducted large, long-term trials measuring average percent weight loss from baseline.
SURMOUNT Trials (Tirzepatide)
- • SURMOUNT-1 (non-diabetic adults): 22.5% average weight loss at 72 weeks.
- • SURMOUNT-2 (type 2 diabetes): ~15% average weight loss, still higher than Semaglutide in diabetes cohorts.
- • Higher doses (12.5 mg and 15 mg) delivered the largest weight reductions.
Source: JAMA, 2022
STEP Trials (Semaglutide)
- • STEP-1 (non-diabetic adults): 14.9% average weight loss at 68 weeks.
- • STEP-2 (type 2 diabetes): ~9.7% average weight loss.
- • Many patients achieved ≥10% total body weight reductions, especially when combined with lifestyle support.
Source: NEJM, 2021
Individual results vary significantly and depend on adherence, titration, and medical history. Clinical trial averages do not guarantee personal outcomes.
Side Effects Comparison
Gastrointestinal side effects are common to all GLP-1 medications because they slow digestion and impact hunger hormones. Most side effects occur during the first 4-8 weeks of titration and often improve with hydration, balanced meals, and slower dose increases.
| Side Effect | Mounjaro | Wegovy |
|---|---|---|
| Nausea | 24% | 20% |
| Vomiting | 8% | 8% |
| Diarrhea | 18% | 16% |
| Constipation | 11% | 9% |
Less common side effects include gallbladder issues, pancreatitis warnings, and possible thyroid C-cell tumors in rodents. Report side effects to your provider immediately.
Dosing Schedules
Both medications use once-weekly injectable pens with gradual titration to minimize GI side effects. Never adjust your dose without provider guidance.
Mounjaro / Tirzepatide
| Weeks 1-4 | 2.5 mg | Starting dose |
| Weeks 5-8 | 5 mg | Initial therapeutic dose |
| Weeks 9-12 | 7.5 mg | Based on response |
| Weeks 13-16 | 10 mg | |
| Weeks 17-20 | 12.5 mg | |
| Week 21+ | 15 mg (max) |
Wegovy / Semaglutide
| Weeks 1-4 | 0.25 mg | Starting dose |
| Weeks 5-8 | 0.5 mg | |
| Weeks 9-12 | 1.0 mg | |
| Weeks 13-16 | 1.7 mg | |
| Week 17+ | 2.4 mg (maintenance) |
Cost Comparison
GLP-1 medications remain expensive, especially at retail pharmacies. Telehealth clinics offering compounded versions provide more accessible pricing, but costs still vary widely based on formulation, membership fees, and shipping.
Brand Retail Pricing
$1,000 - $1,350 / month
Insurance approval or manufacturer savings cards may reduce this.
Who Should Choose Mounjaro?
Consider discussing Tirzepatide with your provider if:
- You have significant weight loss goals (30-50+ pounds) and can tolerate gradual titration.
- You also have type 2 diabetes and want improved glycemic control.
- Your budget allows for higher monthly costs or insurance coverage.
- You prefer the latest clinical data showing higher average weight loss.
Who Should Choose Wegovy?
Semaglutide may be a better fit if:
- You want a proven medication with several years of real-world data.
- You are budget-conscious and prefer the lowest telehealth pricing tiers.
- You are early in your weight loss journey and looking for gradual, steady results.
- You prefer to start with a GLP-1 before considering dual-agonist therapy.
Brand vs Compounded Options
Brand-name medications are FDA-approved and dispensed through pharmacies with manufacturer oversight. Compounded versions are prepared by 503A/503B compounding pharmacies when brand options are cost-prohibitive or inaccessible. Compounded medications should only be sourced from reputable clinics that disclose their pharmacy partners and follow FDA guidance.
How to Get Started
Regardless of which medication you’re considering, the process involves medical oversight:
- Consult with your primary care provider or a licensed telehealth clinic.
- Undergo a medical evaluation (questionnaire, lab work, or video visit).
- Discuss your health history, medications, and goals to confirm eligibility.
- Receive a prescription if the provider determines it is appropriate.
- Follow dosing instructions, nutrition guidance, and follow-up visits.
We are not a pharmacy or telehealth provider. We do not prescribe or sell medications.
Frequently Asked Questions
Is Mounjaro stronger than Wegovy?
Clinical trial data suggest Tirzepatide (Mounjaro) delivers higher average weight loss (up to ~22.5%) compared with Semaglutide (Wegovy) at ~15%. However, “stronger” depends on your health profile, tolerability, and cost considerations. Some patients respond well to Wegovy’s GLP-1–only mechanism and prefer its longer track record. Only a licensed provider can determine which is appropriate.
Can you switch from Wegovy to Mounjaro?
Yes, under medical supervision. Many patients transition when they need more aggressive weight loss or if they plateau on Semaglutide. You must work with a licensed healthcare provider to plan the switch, manage titration, and monitor side effects.
Which has fewer side effects?
Both medications have similar gastrointestinal side effects (nausea, vomiting, diarrhea, constipation). Because Tirzepatide is a dual agonist, some patients report slightly more GI discomfort, while others tolerate it better due to faster satiety. Side effects are highly individual—dose titration and lifestyle habits play a large role.
Why is Mounjaro more expensive?
Brand-name Mounjaro currently has higher wholesale pricing and limited manufacturer coupons compared with Semaglutide. Compounded Tirzepatide also requires more complex manufacturing. As demand grows and competition increases, pricing could change, but Wegovy remains the more affordable option at most telehealth clinics.
Our Verdict
Mounjaro (Tirzepatide) delivers the highest average weight loss in clinical trials, making it compelling for patients with significant goals or type 2 diabetes. Wegovy (Semaglutide) remains a powerhouse for long-term, budget-conscious weight management thanks to more affordable compounded options and a long safety record. The “best” option ultimately depends on your health history, budget, and provider guidance.